Cancer Screening and Prevention

Cancer screening and prevention in gynecology aims to detect disease before symptoms appear or to prevent it altogether. Cervical cancer is the paradigm: it has both an effective primary prevention (HPV vaccination) and effective secondary prevention (screening for and treating precancerous lesions), which together make it one of the few cancers targeted for elimination.

Definition

Cancer screening is the systematic testing of asymptomatic people to detect a cancer or its precursor at an early, more treatable stage; in gynecology it is most developed for cervical cancer, combining primary prevention (HPV vaccination) with secondary prevention (cytology and HPV testing).

Scope

This entry covers the principles of screening as they apply to gynecologic cancer, with cervical cancer as the central example because it has a detectable precursor phase and validated tests. It contrasts cervical screening with cancers (such as ovarian) that lack effective screening, and it summarizes the shift from cytology to HPV-based screening. It is a reference topic and does not provide individualized screening or treatment recommendations.

Core questions

• What makes a cancer suitable for population screening?
• Why is cervical cancer screenable while ovarian cancer is not?
• How does HPV-based primary screening compare with cytology?
• How do vaccination and screening combine in cervical cancer prevention and elimination efforts?

Key concepts

• Primary versus secondary prevention
• Detectable precursor (precancer) phase
• Cervical cytology (Pap test)
• Primary high-risk HPV testing
• Sensitivity, specificity, and overdiagnosis
• Screening interval and triage
• Cervical cancer elimination strategy

Mechanisms

Effective screening depends on a disease having a detectable preclinical phase and a test that can find it accurately. Cervical cancer fits this model because high-risk HPV infection produces precancerous intraepithelial lesions over years, allowing detection and treatment before invasion. Cytology (the Pap test) historically reduced cervical cancer incidence, and randomized trials later showed that primary HPV-based screening provides greater protection against invasive cervical cancer than cytology because of its higher sensitivity for precancer (Ronco, 2014). Major guidelines have correspondingly shifted toward HPV-based screening at extended intervals (USPSTF, 2018; Fontham, 2020). Primary prevention through HPV vaccination reduces the precancers that screening would otherwise detect (Lei, 2020). In contrast, cancers such as ovarian lack a precursor that screening can reliably catch, so no effective screening exists for them.

Clinical relevance

Understanding screening principles clarifies why organized cervical screening and vaccination have driven large declines in cervical cancer and why elimination is considered feasible, while also explaining the limits of screening for cancers without a usable precursor. This entry describes screening concepts for reference and is not a source of individualized screening schedules or clinical advice.

Epidemiology

Where organized vaccination and screening programs exist, cervical cancer incidence and mortality have fallen markedly; where they are lacking, the burden remains high, producing the global disparities documented by Arbyn and colleagues (2020). These patterns motivate the World Health Organization's strategy to eliminate cervical cancer as a public-health problem through vaccination, screening, and treatment of precancer.

History

Cervical cytology, introduced by George Papanicolaou in the mid-twentieth century, was among the first successful cancer-screening tools and substantially reduced cervical cancer where applied. The recognition of HPV as the cause of cervical cancer reframed screening around viral detection; randomized trials then demonstrated the superiority of HPV-based screening (Ronco, 2014), and guidelines were updated accordingly (USPSTF, 2018; Fontham, 2020). The combination of vaccination and screening underpins current elimination goals.

Debates

Optimal screening test and interval

Primary HPV testing is more sensitive than cytology but less specific, raising questions about ideal screening start age, intervals, triage of HPV-positive results, and the role of self-sampling, which guidelines continue to refine.

Screening for cancers without a precursor

For cancers such as ovarian, no screening strategy has reliably reduced mortality, illustrating that screening only works when a detectable preclinical phase and an accurate test both exist.

Key figures

• Guglielmo Ronco
• Joakim Dillner
• Marc Arbyn
• George Papanicolaou

Seminal works

• ronco-2014
• uspstf-2018
• fontham-2020

Frequently asked questions

Why has cervical cancer screening shifted from the Pap test to HPV testing?

Randomized trials showed that primary high-risk HPV testing detects precancer more sensitively than cytology and gives greater protection against invasive cervical cancer, so many programs now use HPV testing as the primary screen.

Why is there no routine screening for ovarian cancer?

Ovarian cancer lacks a reliably detectable precursor phase and an accurate early test; trials of screening have not shown a reduction in deaths, so routine screening of average-risk individuals is not recommended.